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Aim To evaluate the relationship between the dynamics of 
proton magnetic resonance spectroscopy (1H-MRS) brain 
metabolite levels at the beginning of the recovery phase of 
the index depressive episode and the time to the recurrence 
of depression.
Methods This retrospective cohort study analyzed the 
changes in N-acetyl aspartate (NAA), choline (Cho), and glu-
tamate-glutamine in 48 patients with recurrent depression 
treated with maintenance antidepressant monotherapy at a 
stable dose. 1H-MRS was performed at the start of the recov-
ery phase and 6 months later. 1H-MRS parameters, index epi-
sode descriptors, and depressive disorder course were ana-
lyzed by Cox proportional hazards model.
Results NAA and Cho decrease six months after the begin-
ning of the recovery period were time-independent risk fac-
tors for depressive episode recurrence. Hazard ratio associated 
with NAA decrease was 2.02 (95% confidence interval 1.06-
3.84) and that associated with Cho decrease was 2.06 (95% 
confidence interval 1.02-4.17). These changes were not relat-
ed to symptoms severity, as Montgomery-Asberg Depression 
Scale score remained generally unchanged (mean -0.01; stan-
dard deviation 1.6) over the first 6 months of recovery.
Conclusion Patients receiving maintenance antidepressant 
therapy after recovery who experience a decrease in NAA or 
Cho levels early in the recovery phase have a double risk of 
depressive episode recurrence. Sustained NAA and Cho lev-
els at the beginning of the recovery phase may indicate in-
creased brain resilience conferred by antidepressant therapy, 
while NAA and Cho decrease may indicate only the trait-relat-
ed temporal effect of therapy in another stratum of patients.
Choline and N-acetyl aspartate 
levels in the dorsolateral 
prefrontal cortex at the 
beginning of the recovery 
phase as markers of increased 
risk for depressive episode 
recurrence under different 
duration of maintenance 
therapy and after it: a 
retrospective cohort study
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With lifetime prevalence of up to 15%, the burden of de-
pression in the form of mortality (suicide, cardio- and cere-
brovascular risk), loss of quality of life, and psychosocial and 
work disability, amounts to significant impairment on mul-
tiple levels of functioning (1). We now accept the Kraepe-
linian view of affective disorder as having a remitting and 
recurring course, with some residual symptoms persisting 
in a number of patients even after entering remission (eg, 
cognitive symptoms) (1,2). Although there are different 
ways of conceptualizing and defining remission, recovery, 
relapse, and recurrence, we generally define remission by a 
significant reduction in symptoms lasting for a specific time 
period (3 consecutive weeks). It is largely considered that 
recovery is achieved after at least 4 months of remission 
without a relapse (3-5). Depression recurrence is defined 
as a new depression episode after the onset of recovery 
phase, although some authors question any meaningful 
difference between relapse and recurrence (3,5).
A study of 175 outpatients treated with antidepressants for 
6 months, and monitored for one year, showed that 46% 
of those who were not depressed at 6 months had anoth-
er episode of depression (6). Another study indicated that 
the recurrence rate after 15 years in primary care popula-
tion was around 35%, while in specialized mental health 
settings it rose to as high as 85% (7). The risk of repeated 
depressive episode decreases over time spent in recovery 
without recurrence, but it also becomes more pronounced 
after each subsequent episode, rising to above 90% after 
3 episodes and approaching 100% without prophylactic 
treatment (8,9). Most important predictors of repeated de-
pressive episode are residual symptoms and the number 
of previous episodes, but also early onset, family history of 
recurrent depression, history of dysthymic disorder, severi-
ty of the first or index episode, as well as negative cognitive 
patterns, high neuroticism, poor social support, and stress-
ful life events (8,10,11).
Research consistently confirms significant reduction in the 
odds of relapse with antidepressants treatment, but given 
the long-term nature of depressive disorders and the risk 
of recurrence there is an ongoing debate on the recom-
mended treatment duration (12,13). Most guidelines rec-
ommend continued treatment for 4-6 months after a de-
pression episode, and there is evidence for the benefit of 
longer maintenance treatment (13,14).
The dorsolateral prefrontal cortex (DLPFC) is considered as 
a region of interest in depression. Changes in its activity 
relative to the phase of illness and treatment, and strong 
indications of neurodegenerative processes in the DLPFC 
as a result of relapse and illness chronicity are well docu-
mented (15-17). Proton magnetic resonance spectrosco-
py (1H-MRS) allows for the evaluation of changes in brain 
metabolites in vivo, and can improve our understanding of 
neuronal changes in the brain on molecular and submo-
lecular levels. 1H-MRS can identify various neurochemicals, 
such as N-acetyl aspartate (NAA) and choline-containing 
metabolites (Cho). They are usually reported as a ratio to 
creatine (Cr), as its brain levels are considered to be rela-
tively stable. Glutamate, glutamine, and gamma aminobu-
tyric acid (GABA) metabolites are commonly combined in 
glutamate-glutamine (Glx) peak due to their overlap. NAA 
with its presence in neurons is considered to be a puta-
tive marker of neuronal integrity and functionality (18-20). 
Previous research has shown NAA changes following vari-
ous modalities of antidepressant treatment (21,22). Cho is 
considered to be a potential marker of cellular membrane 
turnover, and previous research reported elevated Cho/Cr 
ratio in ventral prefrontal white matter bilaterally after 12 
weeks of treatment with selective serotonin reuptake in-
hibitors (SSRIs) (23). Reduced Glx values in the prefrontal 
cortex of depressed patients correlate with disease sever-
ity, and GABA levels normalize following antidepressant 
treatment (24-26). Further longitudinal research on the 
DLPFC and other frontal regions is warranted in order to 
determine functional relevance of metabolite changes in 
depression treatment (27).
Our previous 1H-MRS study on the same cohort of pa-
tients evaluated the risk of depressive symptoms recur-
rence in patients on a stable dose of antidepressant in 
maintenance therapy. Patients who experienced recur-
rence during maintenance treatment were compared with 
those who entered the discontinuation of antidepressants 
phase (28). Decreased Cho/Cr and NAA/Cr ratios after re-
covery were related to an elevated risk for recurrence dur-
ing maintenance therapy, and decreased Cho/Cr was as-
sociated with a 2.7-fold increase in the risk of depression 
recurrence (28).
The main shortcoming of our past research was that the 
end-point of the study was defined as either start of anti-
depressant withdrawal or recurrence of a depressive epi-
sode, whatever occurs earlier. The present study aims to 
provide more detailed insight into correlates between 
neurochemical changes and clinical outcomes of initi-
ated maintenance therapy, without imputing future 
knowledge on treatment resolution to a historical time 
point, so to avoid a “recurrence agnostic” approach. 
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For this purpose, we collected data on eventual recurrent 
episodes for patients who survived episode-free to medi-
cation withdrawal point and analyzed survival data for all 
recruited patients. We hypothesize that restructuring of 
the DLPFC continued in the recovery period and would 
reflect in an increase in NAA and Cho levels at the recov-
ery, both markers contributing to longer episode-free sur-
vival period.
PARTiCiPANTS AND METHODS
This retrospective cohort study was performed in patients 
with recurrent depression who participated in past or on-
going research on identification of predictors of therapeu-
tic response (28). The patients were diagnosed according 
to International Classification of Diseases (ICD)-10, and the 
diagnosis was confirmed by Mini International Neuropsy-
chiatric Interview (MINI) 5.0 (29). We identified 48 patients 
who had (a) MRS scans of the DLPFC at the start of the 
recovery period, (b) a follow-up MRS scan 6 months later, 
and (c) who were on maintenance antidepressant therapy 
since entering the recovery phase (Figure 1).
Definition of recovery was based on the standard criterion 
of a Montgomery-Asberg Depression Scale (MADRS) score 
≤10 (30), and MRS scan was performed on the day of clini-
cal evaluation (or at the latest 2 days following clinical eval-
uation). The first 1H-MRS evaluations were done within 4 
months of remittance of the depressive symptoms (recov-
ery phase) and the second evaluations were done 6 months 
after. Patients continued with prescribed maintenance 
therapy either until withdrawal (beginning of tapering off 
of antidepressant) or until the recurrence of the depres-
sive episode. There were no specific study requirements 
regarding the choice of antidepressant medication, condi-
tions for the antidepressant change, or the antidepressant 
treatment duration, and these decisions were made by the 
three attending psychiatrists at the Neuron Polyclinic. Pa-
tients were assessed on outpatient basis by psychiatric in-
terviews and MADRS at least every 6 months and followed 
up until their next depressive episode. Monotherapy with 
antidepressants was used (following Summary of Product 
Characteristics for each of the individual antidepressants), 
and for some patients a stable dose of medication from 
benzodiazepine class, but no other additional therapeutic 
interventions (eg, psychotherapy), was used. Study proto-
col was formulated in accordance with the Declaration of 
Helsinki, and was approved by the Ethics Committee of the 
University of Zagreb School of Medicine (No. 04-1423-2006 
of February 17, 2006) and the Ethics Committee of Poly-
clinic Neuron (No. 17-06 of March 23, 2006). All included 
patients previously signed informed consent for the par-
ticipation in long-term evaluations. First person first visit 
and last person last visit were in April 2006 and July 2008, 
respectively.
1H-MRS was performed by two trained radiologists (MaR 
and MiR), blinded to the participants’ diagnosis using a 
2.0 T system (Gyrex 2T-Prestige, GEMS/Elscint, Haifa, Israel) 
with a quadrate head coil. Head motion was minimized 
using foam pads, and the intersection of the frontal bone 
and two nasal bones (nasion) was used as a landmark for 
the scan. The voxels were repositioned in the area of inter-
est – the left DLPFC, and spectroscopic volume of inter-
est (15 × 15 × 15 mm) was selected in that region in order 
to minimize the amount of cerebrospinal fluid contained 
FiguRE 1. Study course and recurrence with respect to the phase during which it took place. *Duration of maintenance antidepres-
sant therapy, tapering-off, and discontinuation were determined by attending clinicians and vary between cases. Figure illustrates 
only relative temporal relationship between scans, maintenance antidepressant therapy, its discontinuation, and recurrences. The 
distance between the elements in the illustration is not to be interpreted as a scaled-down version of real temporal relationships. 
1H-MRS - proton magnetic resonance spectroscopy.
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in the volume of interest. A point-resolved spectroscopy 
sequence was used (1500/35 [TR/TE – repetition time/
echo time), with 100 averages. The spectra were reevalu-
ated for peak NAA (at 2.02 ppm), Cho (at 3.2 ppm), Glx 
(at 2.2-2.4 ppm), and Cr (at 3.03 ppm). We used absolute 
NAA, Cho, and Glx values, as well as their ratios to Cr. The 
software package program supplied by the manufacturer 
(Gyrex 2T-Prestige, GEMS/Elscint) was used in the analysis 
of spectral data set.
Statistical analysis
Candidate markers of prognosis entered into the analysis 
included brain metabolites in the region of interest (DLP-
FC), factors previously identified as important based on 
our current knowledge regarding recurrence of depres-
sive episodes, and a set of factors that might modify the 
levels of analyzed brain metabolites. The model entered 
into Cox proportional hazards (CPH) analysis initially con-
sisted of three sets of variables: 1) changes in NAA, Cho, 
and Glx expressed as ratio to Cr; 2) three variables describ-
ing the course of the last/index episode (time to remis-
sion, MADRS score improvement till recovery, and change 
in the MADRS score between the start of the recovery and 
6-months follow-up); and 3) three variables describing the 
previous course of recurrent depressive disorder (age of 
the onset of the first episode, years lived with depression, 
and number of prior episodes). Forward stepwise likeli-
hood ratio model was used. We checked proportional 
hazard assumption by constructing a product between 
the variable and a linear function of time, added an in-
teraction term, and tested for its significance. After sig-
nificant parameters were identified in the initial model, a 
model with dichotomized variables was developed (using 
overall direction of change and not the level of increase/
decrease) in order to ensure easier identification and in-
terpretation of changes in brain metabolites. The level of 
statistical significance was set at 0.05. Statistical analysis 
was performed in Statistica software package, version 13.2 
(Dell Inc., Round Rock, TX, USA, licensed to the University 
of Zagreb School of Medicine).
RESulTS
The study included 30 female and 18 male patients at the 
start of their recovery phase. Recurrent episode was doc-
umented in 43 patients. In 20 patients, a new depression 
episode occurred while on maintenance therapy, and in 
23 the initiation of antidepressant tapering off took place 
before the occurrence of another episode. With regards to 
5 remaining patients, 2 were lost to follow-up, 2 converted 
to bipolar affective disorder, and 1 experienced serotoner-
gic syndrome and was taken off of antidepressant.
The mean survival after the beginning of the recovery pe-
riod (time of initiation of maintenance therapy) was 3.2 years 
(standard deviation [SD] = 2.0; Table 1). In 23 patients who 
went through antidepressant tapering off, recurrent epi-
sode appeared on average 1.4 years after its start (SD = 1.0).
Escitalopram was the most frequently used antidepressant 
(in 13 patients), followed by sertraline (n = 10), fluoxetine 
(n = 5), venlafaxine (n = 4), mirtazapine (n = 3), paroxetine 
(n = 3), citalopram (n = 2), amitriptyline (n = 2), reboxetine 
(n = 2), fluvoxamine (n = 2), moclobemide (n = 1), and imip-
ramine (n = 1). According to Neuroscience-based Nomen-
clature-2 classification, the vast majority of antidepressants 
were reuptake inhibitors: serotonin transporter (n = 35); se-
rotonin and norepinephrine transporters (n = 7); and nor-
epinephrine transporter (n = 2). Three patients were treat-
TABlE 1. Descriptors of the disorder course and index episode
Characteristic N Mean (standard deviation) Range
Disorder course descriptors
age at onset of disorder 48 28.41 (8.57) 17-46
years lived with depression 48 15.4 (10.5)  2.0-40.8
No. of prior episodes 48  3.8 (2.0)  2-12
Current/index episode descriptors
months to remission 48  5.7 (1.5)  2.7-8.9
Montgomery-Asberg Depression Scale score
at the beginning of an episode 48 25.6 (4.1) 18-34
at the start of the recovery phase 48  5.4 (1.2)  3-9
at 6 months after the start of the recovery phase 48  5.4 (1.1)  2-8
at the last evaluation (recurrence) 43* 20.9 (2.3) 18-29
*2 patients were lost to follow-up, 2 converted to bipolar affective disorder, and 1 experienced serotonergic syndrome and was taken off of antide-
pressant.
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ed with receptor antagonist (NE alpha-2, 5-HT2, 5-HT3) and 
1 with reversible enzyme inhibitor.
Overall MADRS score significantly improved from the be-
ginning of an episode to the start of the recovery phase, 
on average by 20.3 points (SD = 3.9.0), and did not change 
significantly in the following 6 months (-0.07; SD = 1.6).
In the overall sample (Figure 2), Cho/Cr ratio increased 
significantly after 6 months (0.06; 95% confidence inter-
val [CI] 0.028 to 0.092; P < 0.001), NAA/Cr increased mod-
erately and non-significantly (0.037; 95% CI -0.031-0.106 
to 0.106; P = 0.279), and Glx/Cr levels were nearly stable 
(0.014; 95% CI -0.055 to 0.083; P = 0.686). Only 14 out of 
48 patients (29.2%) experienced a decrease in Cho/Cr, 
whereas nearly half of the patients experienced a de-
crease in NAA/Cr (23 patients, 47.9%). Changes in these 
two metabolites were not directly related to each other, 
as NAA/Cr decreased concurrently only in about half (8 
of 14) of the patients who experienced Cho/Cr decrease. 
Changes in brain metabolites were not related to symp-
toms severity.
In CPH analysis, none of the time-dependent covariates 
was significant (P values of these covariates for NAA/Cr, 
Cho/Cr and Glx/Cr were 0.089, 0.218 and 0.721, respective-
ly). This confirmed that there was no significant time-vary-
ing effect. In the assessment of proportionality assump-
tion, constant hazard ratios were also confirmed visually by 
inspecting plot of the log(-log(S(t)) functions (Table 2).
Only two variables out of 9 entered into the initial CPH 
model had a significant contribution based on the inspec-
tion of beta coefficients, risk ratios with their 95% CI, t-val-
ue approximations, and Wald statistics. The two variables 
with significant contributions were the change in NAA/
Cr and Cho/Cr, whereas all others had considerably lower 
contribution. This was further confirmed when all 9 vari-
ables were entered into CPH forward stepwise likelihood 
ratio model with two steps. After the inclusion of Cho/Cr 
change in the first step of the model (B = -3.762; SE = 1.495; 
Wald = 6.330; df = 1; P = 0.012; Exp(B) = 0.023), the final mod-
el (-2 log likelihood = 239.936; χ2 = 10.869; df = 2; P = 0.04) 
consisted of two variables: Cho/Cr change (B = -4.098; 
SE = 1.545; Wald = 7.033; df = 1; P = 0.008; Exp(B) = 0.017), 
TABlE 2. Parameter estimates of the initial model
Factor Relative risk (95% confidence interval) P
1H-MRS metabolite changes 6 months after recovery
N-acetyl aspartate/creatine 0.084 (0.015-0.480) 0.005
choline/creatine 0.013 (0.001-0.328) 0.008
glutamate-glutamine/creatine 0.302 (0.062-1.459) 0.136
Current episode descriptors
months to remission 0.847 (0.639-1.121) 0.245
MADRS improvement at recovery 1.065 (0.972-1.167) 0.178
MADRS change 6 months after recovery 1.075 (0.857-1.350) 0.531
Disorder course descriptors
age at onset 0.993 (0.947-1.042) 0.776
years lived with depression 0.973 (0.934-1.014) 0.195
No. of prior episodes 1.101 (0.899-1.349) 0.351
*1H-MRS – proton magnetic resonance imaging; MADRS – Montgomery-Asberg Depression Scale.
TABlE 3. Parameter estimates of the final model
Factor Relative risk (95% confidence interval) P
1H-MRS metabolite changes 6 months after recovery
N-acetyl aspartate/creatine 0.238 (0.061-0.921) 0.038
choline/creatine 0.016 (0.001-0.340) 0.008
After dichotomization (only rise or fall monitored)
N-acetyl aspartate/creatine remains equal or rises 1
N-acetyl aspartate/creatine decreases 2.015 (1.056-3.844) 0.034
choline/creatine remains equal or rises 1
choline/creatine decreases 2.063 (1.021-4.167) 0.044
*1H-MRS – proton magnetic resonance imaging.
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and NAA/Cr change (B = -1.424; SE = 0.690; Wald = 4.258; 
df = 1; P = 0.039; Exp(B) = 0.241; Table 3).
The model was not significantly improved by dichotomi-
zation of variables and the inclusion of composite risk of 
concomitant Cho/Cr and NAA/Cr direction of changes. Pa-
tients who had a decrease in Cho/Cr after remission were at 
a 2.06 higher risk to experience recurrent episode than pa-
tients in whom Cho/Cr ratio remained stable or increased, 
and those who had NAA/Cr decrease were at a 2.02 high-
er risk at any given point of time after recovery. The final 
dichotomized model pointed to Cho/Cr and NAA/Cr de-
creases as highly predictive variables for the recurrence of 
a depressive episode.
DiSCuSSiON
This study showed that the failure to achieve a rise or at 
least sustain equal NAA and Cho levels in the DLPFC in the 
first six months of recovery phase was associated with a 
doubled risk of the recurrent depressive episode. Identified 
risks did not display a time-varying effect, so they remained 
the same during the remaining recovery period.
In line with our previous work, some studies report NAA/
Cr increase in the frontal brain regions after SSRI therapy, as 
well as a Cho increase, but they mostly evaluated patients 
until entering remission or shortly after it was achieved 
(16,22,23,31-33). Our research group already reported an 
increase in Cho/Cr ratio in the DLPFC during antidepres-
sant treatment in early to intermediate responders after 3-6 
weeks of SSRI treatment in recurrent depression comorbid 
to posttraumatic stress disorder (34). Our previous report 
on the same sample of patients showed that decreased 
Cho/Cr ratio at the onset of recovery phase predicted de-
pression recurrence in patients on maintenance therapy, 
and that these patients also exhibited decreased NAA/Cr 
ratio (28). Our present study focused on all the patients 
who had depression recurrence whether during mainte-
nance therapy or after the antidepressant withdrawal. By 
not assuming the knowledge of a future outcome in the 
present (as in everyday practice), the approach that disre-
gards the duration and outcome of future maintenance 
therapy offers a more clinically relevant way of looking at 
recurrence, and suggests the possibility of using NAA and 
Cho as 1H-MRS markers of longer remission/recovery time 
before depression recurrence.
The symptoms severity after entering recovery did not 
change significantly in the observed period. Since a time-
varying effect was rejected, it appears that the changes in 
metabolite levels could not be connected to an imminent 
worsening of patients’ condition, which we would expect 
to closely follow the decrease of Cho and NAA metabo-
lites. Observed changes in metabolite levels independent 
of severity, and their prolonged effect, lead us to the as-
sumption that antidepressant therapy may be related to 
a temporary improvement (supportive or “symptomatic”) 
and longer-term brain adaptability or resilience. Sustained 
NAA and Cho levels at the beginning of the recovery phase 
may indicate increased brain resilience influenced by an-
tidepressant therapy, but decreased NAA and Cho levels 
may also indicate only the trait-related temporal effect of 
therapy in another stratum of patients.
Interestingly, our results may indicate the therapy (anti-
depressant)-triggered increase in membrane turnover rate 
in the DLPFC. The observed ratio changes may be the con-
sequence of phosphorylcholine-to-glycerophosphoryl-
choline mediated synthesis-to-breakdown overbalance, a 
finding that would be congruent to functional connectivity 
changes observed in neuroimaging studies of the DLPFC 
(35,36). Consistent with our previous study (28), we dem-
onstrated that metabolic changes in the brain suggesting 
an increase in neuronal integrity and membrane turnover 
continue beyond the acute treatment and remission phas-
es, for at least 6 months after the initiation of maintenance 
antidepressant therapy. We do not know for how long 
these changes persist, but this finding certainly warrants 
the initiation of MRS studies of a considerably longer 
duration than is our current scientific practice.
FiguRE 2. Magnetic resonance spectroscopy measurements of 
N-acetyl aspartate/creatine (NAA/Cr), choline-containing me-
tabolites/creatine (Cho/Cr), and glutamate-glutamine/creatine 
ratios (means and 95% confidence intervals).
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Significant metabolite level differences, observed 6 months 
after the start of recovery, may represent the continuation 
of a trend in metabolite rise that began at a yet unknown 
time preceding the recovery phase. If this trend exists, it 
is impossible to assume whether it is linear or not. Given 
that significant variability of the time for antidepressant re-
sponse is well documented, it is likely that metabolites do 
not start to increase uniformly over time in all patients. This 
presumed different time-origin of the trend may underlie 
a wide variability of MRS findings observed in acute and 
remission phases.
Shorter average time to remission (5.7 weeks) in this group 
of patients is consistent with lower depression severity at 
baseline (MADRS of 25.6). Because of the limited range of 
severity of episodes in our sample, we could not assess the 
degree to which baseline severity of an episode affected 
the observed metabolite changes. Also, some previously 
identified risk factors for recurrence were not included in 
the analysis (eg, residual symptoms prior to index episode) 
because verifiable and reliable data on these risk factors 
could not be gathered for this sample.
It is important to stress the retrospective design as a limi-
tation of our study. Designing and conducting similar but 
prospective studies with multiple scan points would help 
with better sample stratification. Also, studies with larg-
er samples are needed, as the present study did not have 
enough power for any meaningful sensitivity and specificity 
assessment that would warrant the use in clinical practice. 
In addition, future studies will need to determine possible 
effects of non-pharmacological interventions, as increase 
in Cho was also observed with sleep restriction and tran-
scranial magnetic stimulation (27). All of this would help in 
discerning the exact nature of metabolite changes as only 
indirect correlates of different biological processes, or as di-
rect indicators of processes underlying the disease and di-
recting its course and response to treatment.
1H-MRS research of metabolite changes during different 
phases of illness seems to be indispensable in provid-
ing a more detailed insight into the interplay of specific 
brain metabolites as a putative marker of the longitudinal 
course of depression. New prospective studies with larger 
samples, possibly combining different research modali-
ties (MRS, functional connectivity imaging) should make 
it possible to answer remaining questions and confirm al-
ready formed hypotheses, but also to make significant 
progress in clinical practice. Outcome predictors and 
the illness course should be identified to help us not 
only clarify underlying neurobiology and pathophysiolog-
ical processes, but to formulate meaningful treatment 
plans with regards to therapy modality and its duration, 
which would reduce the risk of recurrence and the burden 
of depression.
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